Table 1.

The Overview of Potential Therapeutic Strategies Targeting BMI1 in HCC Treatment.

Therapeutic strategies targeting BMI1	Category	Reference
Compounds inhibiting BMI1 expression	PTC-209	66
	PTC-028	67
	PTC-596	68
	QW24	69
	RU-A1	70
Increasing the expression of MicroRNAs downregulating BMI1 level	1,6,7-trihydroxyxanthone(THA) upregulating miR-218	76
	Luteolin and sevoflurane upregulating miR-203	81 to 83
	Short-chain fatty acid sodium butyrate (NaB) upregulating miR-200c	87
Natural extracts suppressing BMI1 expression	Jiedu Xiaozheng Yin (JXY)	88
	Wallichoside	89
Combinations of chemotherapeutical agent and BMI1- siRNA	Nanoplatin and siRNA co-loaded CaP nanoparticles (NPSC) delivering cisplatin and BMI1- siRNA	92
	Nanocapsules delivering BMI1- siRNA and cisplatin cationic	93
Genome editing	Clustered regularly interspaced short palindromic repeats and CRISPR associated protein-9(CRISPR-Cas9)	97 to 99